As part of the deal, Merck would pay $107 per American depository share for Verona, a 23% premium to the biotech’s closing price on Tuesday, Financial Times reports, citing three unidentified people familiar with the matter.
- The takeover values Verona at about $10b
- A deal could be announced as soon as Wednesday
- Merck declined to comment to FT
- Verona did not immediately respond to a request for comment: FT
To view the source of this information, click
(Updates with more details)
To contact the reporter on this story:
To contact the editor responsible ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.